Pharma BD Deal Intelligence
A modest ~$15M tech/product bolt-on that quietly delivered a durable, market-leading generic (glipizide ER) — a solid single, not the ~$100M-scale deal the brief assumed.
Full analysis, sources & comparables →Amarin announced the sale of Amarin Development AB to Watson Pharmaceuticals, with Watson paying approximately $15 million in cash to settle inter-company…
Watson's 2003 10-K disclosed acquisition of Amarin Development AB and the related oral controlled-release drug-delivery technology portfolio, including…
Amarin disclosed treatment of the Swedish drug-delivery business sale to Watson as a discontinued operation with installment proceeds, indicating…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Acquired Amarin Development AB in October 2003. Oral controlled-release drug delivery technologies + glipizide ER. Sources: Watson 10-K 2003, Amarin filings. Value approximate from 10-K disclosures.
A modest ~$15M tech/product bolt-on that quietly delivered a durable, market-leading generic (glipizide ER) — a solid single, not the ~$100M-scale deal the brief assumed.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) (this deal) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2003 deals · Watson Pharmaceuticals (Actavis Inc.) deals